Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tatva Chintan Pharma Chem's Revenue for the
three
months ended in Jun. 2026 was ₹1,671 Mil. Tatva Chintan Pharma Chem's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹1,190 Mil.
Hence, Tatva Chintan Pharma Chem's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.40.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tatva Chintan Pharma Chem Receivables Turnover Related Terms
Tatva Chintan Pharma Chem Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:TATVA vs LIN, SHW, ECL: Receivables Turnover Comparison
For the Specialty Chemicals subindustry, Tatva Chintan Pharma Chem's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tatva Chintan Pharma Chem Receivables Turnover vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Tatva Chintan Pharma Chem's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tatva Chintan Pharma Chem's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tatva Chintan Pharma Chem (NSE:TATVA) has a Receivables Turnover of 1.40 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tatva Chintan Pharma Chem and its competitors. According to the industry distribution chart, Tatva Chintan Pharma Chem ranks #833 out of 1583 companies in the Chemicals industry, placing it in the top 52.6%.
Is Tatva Chintan Pharma Chem's Receivables Turnover too high?
Tatva Chintan Pharma Chem's current Receivables Turnover is 1.40. The Chemicals industry median Receivables Turnover is 5.70. Tatva Chintan Pharma Chem's value of 1.40 is 75.4% below this industry median. Based on the distribution chart, Tatva Chintan Pharma Chem ranks #833 out of 1583 companies in the Chemicals industry, which is below the industry midpoint. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's Receivables Turnover compare to LIN and SHW?
According to the Chemicals industry distribution chart, Tatva Chintan Pharma Chem ranks #833 out of 1583 companies for Receivables Turnover. This places Tatva Chintan Pharma Chem in the lower half of its industry. The industry median Receivables Turnover is 5.70. Tatva Chintan Pharma Chem's value of 1.40 is 75.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Chemicals company?
The median Receivables Turnover among Chemicals companies is 5.70, based on 1,583 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tatva Chintan Pharma Chem's current Receivables Turnover of 1.40 is 75.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tatva Chintan Pharma Chem and its competitors. For the Chemicals industry, the median Receivables Turnover is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tatva Chintan Pharma Chem's current Receivables Turnover is 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,523.85, compared to a current price of ₹1,616.40 — trading 6.1% above its estimated fair value. The current Receivables Turnover is 1.40 and 75.4% below the Chemicals industry median of 5.70. Tatva Chintan Pharma Chem's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current Receivables Turnover is 1.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be overvalued.
The current stock price of ₹1,616.40 is trading 6.1% above its estimated GF Value™ of ₹1,523.85.
GuruFocus considers Tatva Chintan Pharma Chem to be Fairly Valued.
Key valuation signals for NSE:TATVA:
Receivables Turnover: 1.40
GF Value™: ₹1,523.85 vs. price of ₹1,616.40 (6.1% above fair value)
Industry Position: 75.4% below the Chemicals median (#833 of 1583)
No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
81GF Score
Get the complete analysis for NSE:TATVA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TATVA has been successfully added to your 
